Lifeboat Foundation

For many of these individuals, the response to repotrectinib lasted for several years.

“Repotrectinib can lead to long-term responses for patients with ROS1 fusion–positive lung cancers, including those who have and have not received prior targeted therapy,” said Alexander Drilon, M.D., of Memorial Sloan Kettering Cancer Center, who led the TRIDENT-1 study.

Treatment with repotrectinib also shrank tumors that had spread to the brain, a common location for lung metastases, the researchers reported.

Register for free to get subscriber-only benefits: https://closertotruth.com/If consciousness is 100% physical, we would have to conclude that the same kind…

Synchron on Monday plans to launch an online…

WASHINGTON, April 8 (Reuters) — Synchron Inc, a rival to Elon Musk’s Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company’s chief executive told Reuters.

Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview.

Continue reading “Exclusive: Synchron, a rival to Musk’s Neuralink, readies large-scale brain implant trial” »

Recent research in mice investigates a new, immunotherapy-based approach to treating Alzheimer’s disease aiming to clear toxic protein accumulations in the brain.

From Caltech & NVIDIA

This explains the prospect of #deeplearning on advancing science, #simulation, and design.

“It’s not much you can do about it. Other than fight it and if you fight and you quit, then you are not gonna make it,” he said.

The founders of this Malibu-based class say it challenges the mind and body to work together, getting stronger in the process.

John Wakefield, the creator and co-founder of drumboxing in California, told KCBS, “The connection with rhythm, tying it in with motor skills, really training the brain like you train the body putting it in a situation where it has to react.”

Certain RNA molecules in the nerve cells in the brain last a life time without being renewed. Neuroscientists from Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have now demonstrated that this is the case together with researchers from Germany, Austria and the U.S.

A medication used to treat diabetes appeared to halt the progression of Parkinson’s symptoms in a phase 2 trial of people in the early stages of the disease. While more research is needed to see how large the effect is and how long it might last, the news is encouraging in the hunt for new Parkinson’s treatments.

The challenge: More than 8.5 million people worldwide are living with Parkinson’s, a progressive neurodegenerative disease caused by the loss of brain cells that produce dopamine, which helps neurons communicate.

Common Parkinson’s symptoms include tremors, stiffness, and impaired cognition. Meds that replace dopamine can help alleviate those, but they don’t address the underlying cause — the loss of dopamine neurons — and so the disease progresses.

The startup, a rival to Elon Musk’s Neuralink, launched a registry to recruit patients and healthcare providers for the trial.